"SEER Program" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
| Descriptor ID |
D018426
|
| MeSH Number(s) |
E05.318.308.970.725 N04.452.859.819.725 N05.715.360.300.715.700.725 N06.850.520.308.970.725
|
| Concept/Terms |
SEER Program- SEER Program
- Program, SEER
- SEER Program (National Cancer Institute (U.S.))
- Surveillance, Epidemiology, and End Results Program
|
Below are MeSH descriptors whose meaning is more general than "SEER Program".
Below are MeSH descriptors whose meaning is more specific than "SEER Program".
This graph shows the total number of publications written about "SEER Program" by people in this website by year, and whether "SEER Program" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "SEER Program" by people in Profiles.
-
Temporal trends in pediatric cancer mortality: rare cancers lag behind more common cancers. Pediatr Hematol Oncol. 2025 Feb; 42(1):1-13.
-
Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
-
Racial and Ethnic Survival Disparities in Pediatric Oncology Over Time: An Analysis of the SEER Registry. J Pediatr Surg. 2025 Jan; 60(1):161953.
-
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
-
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol. 2015 Apr; 38(2):165-73.